Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
11 drugs in development
By Therapeutic Area
top 6
R&D Momentum
85/100
Pipeline Velocity
62/100
Trial Completion Rate
75/100
Pipeline Concentration
12/100
Pipeline Freshness
69/100
Strategic Signals
Activity
Last 14 days
Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Pelvic Pain Suggestive of Dysmenorrhea: A Prospective, Multicenter, Double-Blind, Randomized Placebo-Controlled Study.
Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease
Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia
CATAMARAN - Neonatal Cohort : Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)